Prednisolone

Giant Cell Arteritis enters a transformative era as targeted therapies challenge steroids with Cosentyx & Rinvoq reshaping remission benchmarks & patient care The future of GCA treatment lies in precision immunotherapy—offering not just symptom relief but long-term remission, steroid-sparing strategies, and real patient-centric outcomes.” — DataM Intelligence AUSTIN, TX, UNITED STATES, June 9, 2025 / EINPresswire.com / -- Giant Cell Arteritis (GCA) , once confined to the margins of autoimmune treatment innovation, is now witnessing a clinical evolution driven by precision immunology and novel therapeutic strategies. Characterized by inflammation of large and medium-sized arteries—most commonly the temporal arteries—GCA is a formidable diagnosis that poses a significant risk of irreversible vision loss if left untreated. It primarily affects adults over the age of 50, with a higher incidence in women and individuals of Northern European ancestry. Book Your Free CI Consultation Call: https://www.datamintelligence.com/strategic-insights/ci/giant-cell-arteritis-gca For decades, systemic corticosteroids served as the cornerstone of GCA management. While effective in suppressing acute inflammation, they come at the cost of long-term side effects—ranging from osteoporosis to diabetes, hypertension, and increased infection risk. This therapeutic gap has driven an urgent push for disease-modifying therapies that not only suppress flares but reduce or eliminate the need for prolonged steroid use. Epidemiological Snapshot: A Growing Clinical Burden GCA is the most common form of large-vessel vasculitis, with incidence rates ranging from 15 to 30 cases per 100,000 individuals over age 50. The prevalence increases steadily with age, particularly in populations above 70. Although GCA is rare in the broader context of autoimmune diseases, its impact is deeply felt due to the risk of blindness, strokes, and systemic complications. Given its chronic nature and dependency on long-term steroid use, GCA presents a significant burden on healthcare systems, necessitating routine imaging, long-term follow-ups, and management of steroid-related comorbidities. These realities underscore the need for safer, more targeted alternatives. The Rise of Targeted Therapies: From Actemra to Rinvoq The first significant breakthrough in GCA management came with the FDA approval of Tocilizumab (Actemra), an IL-6 receptor antagonist developed by Roche/Genentech. Tocilizumab was the first biologic approved specifically for GCA and has since become a widely accepted standard for patients requiring a steroid-sparing strategy. Its robust data from the GiACTA trial showed significant improvement in sustained remission rates and reduction in steroid dependence. In 2025, Upadacitinib (Rinvoq), a JAK1-selective inhibitor by AbbVie, entered the therapeutic landscape. This oral small molecule offers a novel mechanism and convenient route of administration—setting a new standard for patient-centered treatment. Rinvoq's arrival marks a shift in focus toward therapies that offer not just efficacy but also lifestyle compatibility. Cosentyx: The Next Challenger in the GCA Arena Among the most closely watched developments in GCA treatment is Secukinumab (Cosentyx), Novartis’ IL-17A inhibitor, currently in Phase III development for GCA. Building on promising results from the Phase II TitAIN study, Cosentyx is poised to become the first IL-17-targeting biologic in this space. The TitAIN study focused on patients aged 50 and above with new-onset or relapsing GCA. Participants received either 300 mg of secukinumab or placebo, combined with a prednisolone taper. The outcomes were compelling: 70.1% of patients in the secukinumab arm achieved sustained remission at Week 28, compared to just 20.3% in the placebo group. At Week 52, over 59% of secukinumab-treated patients remained in remission, with a median time to flare not reached—highlighting its durable therapeutic effect. Notably, the safety profile of secukinumab was favorable, with comparable adverse events to placebo. These findings reinforce secukinumab’s potential to offer a true steroid-sparing regimen, which could fundamentally shift the risk-benefit calculus in GCA treatment. Phase III GCAptAIN Trial: What’s at Stake The ongoing GCAptAIN Phase III study will be pivotal in determining secukinumab’s commercial and clinical trajectory. The trial involves 349 participants randomized to receive either 300 mg, 150 mg of secukinumab, or placebo, alongside a glucocorticoid taper. The primary endpoint is sustained remission at Week 52, while secondary outcomes include quality of life measures, time to clinical failure, and cumulative glucocorticoid exposure. With results anticipated later this year, the GCAptAIN trial could solidify secukinumab’s role as a transformative player in the GCA space—especially for patients who do not respond to or tolerate IL-6 or JAK inhibitors. Competitive Landscape: Evolving Standards and Market Dynamics Tocilizumab retains its position as the biological standard of care, backed by long-term efficacy data and well-established use. However, its intravenous/subcutaneous administration routes can be limiting for some patients. Upadacitinib offers a more flexible alternative, particularly attractive for those seeking oral therapy. Its differentiation lies in its convenience and unique mechanism, although concerns about JAK inhibitors’ safety in older adults persist. Secukinumab introduces a novel IL-17 pathway targeting—providing an option for patients who relapse or fail to respond under IL-6 or JAK inhibition. Its monthly dosing and robust efficacy in Phase II offer competitive advantages that could challenge Actemra’s longstanding dominance. As the competitive landscape diversifies, the future market is likely to be stratified by mechanism of action, route of administration, and the ability to deliver long-term remission without the side effects of steroids. Defining the Ideal Therapy: Target Opportunity Profile (TOP) Emerging GCA therapies must meet rigorous clinical and patient-centric benchmarks to secure a sustainable market presence. The ideal therapy would deliver ≥70% sustained remission at 52 weeks, a rapid onset of action within 2–4 weeks, and minimal long-term safety concerns such as infections or cardiovascular risks. Oral administration or infrequent subcutaneous dosing remains highly desirable, particularly for elderly patients with comorbidities. In terms of innovation, future leaders will likely come from therapies that can leverage biomarker-based targeting or precision immunomodulation, especially for steroid-refractory or relapse-prone populations. Differentiated mechanisms, such as IL-17, GM-CSF, or complement pathway modulators, may offer valuable alternatives to existing modalities. Download Free CI Sample Report: https://www.datamintelligence.com/strategic-insights/sample/giant-cell-arteritis-gca The Road Ahead: Precision Immunology Meets Practical Needs The evolution of GCA treatment reflects a broader transformation in autoimmune care—from symptom suppression to disease modification and patient quality of life. As trials like GCAptAIN near completion, clinicians and stakeholders eagerly anticipate a new era where durable remission, safety, and convenience are achievable without compromise. For patients long tethered to the risks of chronic steroid therapy, these advancements signal hope. The combination of scientific precision, strategic positioning, and therapeutic innovation is finally delivering options that not only extend remission but improve the day-to-day lives of those living with GCA. Read Related CI Report: 1. Alpha 1 Antitrypsin Deficiency | Competitive Intelligence 2. Chronic Spontaneous Urticaria | Competitive Intelligence Sai Kiran DataM Intelligence 4market Research LLP 877-441-4866 email us here Visit us on social media: LinkedIn X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Artera shared on Friday that it will present two studies at the American Society of Clinical Oncology (ASCO) meeting featuring the use of its multimodal artificial intelligence (MMAI) model to stratify patients with prostate cancer who will benefit from added treatment and to predict prostate cancer outcomes after prostatectomy."These studies reinforce our commitment to the rigorous clinical validation of the ArteraAI Prostate Test and our broader MMAI platform," said Timothy Showalter, Chief Medical Officer of Artera. "Together, they reflect our mission to empower clinicians and patients with personalised, actionable insights that support confident, shared decision-making in prostate cancer care."Identifying candidates for added therapyThe first study, conducted as part of the STAMPEDE trial, used the ArteraAI Prostate Test to identify patients with high-risk non-metastatic prostate cancer who would benefit most from adding androgen receptor pathway inhibitor (ARPI) abiraterone acetate and prednisolone with or without another ARPI, enzalutamide, to standard of care (SOC) androgen deprivation therapy. While the STAMPEDE trial helped cement ARPIs as the SOC for high-risk patients, treatment responses have varied, and associated adverse events highlight the need for prognostic and predictive biomarkers. When evaluated in 555 patients treated with SOC plus ARPIs and 781 treated with SOC alone, researchers from University College London Cancer Institute found that higher continuous MMAI scores were linked to worse outcomes over a median follow-up of six years. Among the cohort, 25% of men tested positive for a biomarker that signalled they would benefit from treatment with ARPIs; those who tested positive for the biomarker and received ARPI had a 9% risk of prostate cancer-specific mortality over five years compared with a 17% risk for those who received SOC. In contrast, patients without the biomarker did not benefit much from ARPI; those who received ARPI had a 4% mortality risk over five years compared with a 7% risk for those who did not receive it. "While traditional tests flag patients at risk of poor outcomes, they don't personalise treatment decisions," said study author Nick James. "Our collaboration with Artera allows us to uncover patterns invisible to the human eye and optimise treatments like never before. The AI tool allows us to connect beneficial treatments to the patient, while sparing those who may suffer unnecessary side effects, or even premature death, if they receive ARPIs they don't need."Prostatectomy predictionsIn the second study, researchers from the University of California, San Francisco validated a digital pathology-based MMAI model for predicting radical prostatectomy outcomes in patients with and without biochemical recurrence. The procedure is highly effective in localised prostate cancer; however, the researchers reported that 20% to 40% of men who undergo prostatectomy still experience biochemical recurrence within 10 years. Despite this statistic, tools to predict risk and inform treatment choices in this population are still lacking. Analysis of 640 cases with MMAI scores with images and clinical data revealed that after adjusting for post-radical prostatectomy Cancer of the Prostate Risk Assessment (CAPRA-S) score, MMAI scores remained independently associated with any metastasis (hazard ratio [HR] = 1.76) and bone metastasis (HR = 2.72). It was also significantly associated with disease progression in a subset of 561 patients with undetectable prostate-specific antigen following surgery (HR = 1.51). Using a previously established cutoff from patients with biochemical recurrence, those classified as high-risk via MMAI after prostatectomy had a significantly higher 10-year risk of any metastasis (18%) and bone metastasis (16%) compared with low-risk patients (3% and 1%, respectively)."This study validates the radical prostatectomy MMAI model, originally developed in patients with biochemical recurrence, as an independent prognostic tool in both biochemical recurrence and general post-radical prostatectomy settings, even when controlling for a validated clinical risk model," the authors wrote. The findings show that the model could help guide personalised treatment following radical prostatectomy "while offering advantages in accessibility, efficiency and cost compared to existing platforms."